可注射的基于多糖的水凝,具有葡萄糖反应,作为增强糖尿病伤口愈合的免疫调节平台
Minxuan Yang1, Yongbin Xu2, Qingsu Cheng3
1Department of Pharmaceutics and Bioengineering, School of Chemical Engineering, Sichuan University, Chengdu 610065, P. R. China.
ACS applied materials & interfaces
|May 22, 2025
概括
这项研究开发了一种新型的水凝,载有protocatechuic酸和deferoxamine,用于治疗糖尿病伤口. 水凝有效调节免疫微环境,促进更快,高质量的皮肤组织再生.
科学领域:
- 生物材料科学 生物材料科学
- 免疫学 免疫学 免疫学
- 伤口治愈研究研究 伤口治愈研究
背景情况:
- 糖尿病伤口由于免疫微环境失衡而表现出持续的炎症,阻碍了愈合.
- 免疫调节对于加速糖尿病伤口关闭至关重要.
- 开发先进的治疗策略对于管理耐火性糖尿病伤口至关重要.
研究的目的:
- 开发一种基于多糖的新型水凝,加载了原甲酸 (PCA) 和除氧胺 (DFO),用于糖尿病伤口愈合.
- 研究开发的水凝 (POCP@D) 的免疫调节特性和治疗效果,用于全厚糖尿病伤口.
- 评估水凝在促进高质量的皮肤组织再生方面的潜力.
主要方法:
- 使用双重交叉连接策略 (酸乙烯和伊胺键) 制造POCP@D水凝.
- 描述水凝的特性,包括组织粘性,机械强度,可注射性,自我愈合性和药物释放性.
- 对抗菌和抗氧化作用的评估.
- 在糖尿病伤口模型中,体内评估水凝对巨细胞两极分化和伤口愈合的免疫调节作用.
主要成果:
- POCP@D水凝显示出有利的物理化学特性和药物释放动力学.
- 水凝表现出强大的广泛抗菌和抗氧化活性.
- POCP@D有效调节免疫微环境,通过促进M2巨细胞两极分化和减少炎症.
- 水凝显著加速了糖尿病伤口的关闭,促进了原沉积和血管生成,从而导致高质量的组织再生.
结论:
- 开发的POCP@D水凝作为糖尿病伤口治疗的有效免疫调节平台.
- 这种新的水凝通过恢复免疫平衡和促进组织再生来促进先进的愈合.
- POCP@D在治疗耐火性糖尿病伤口方面具有重要的临床应用潜力.
相关概念视频
01:24Glucagon-like Receptor Agonists
281
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
281
01:06Oral Hypoglycemic Agents: Glinides
124
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
124
01:15Hypoglycemia and Glucagon
146
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
146